Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Biogen Idec Inc. (NASDAQ: BIIB) shares declined 0.25 percent to close at $296.72 a share Wednesday. The stock traded between $292.32 and $298.63 on volume 1.04 million shares traded. Stifel Nicolaus analyst Joel Sendek expects the company’s revenue from Avonex to total $2.46 billion in 2014. Shares of Biogen Idec have gained approximately 105.0 percent in the past year.
Get more information on Biogen Idec free access to the in-depth equity report at:
www.FiveStarEquities.com/BIIB
NuVasive, Inc. (NASDAQ: NUVA) shares spiked 8.53 percent to close at $36.66 a share Wednesday. The stock traded between $36.35 and $37.25 on volume of 2.06 million shares traded. The company announced that preliminary revenues for the full year 2013 are expected to be roughly $683.0 million, an increase of 10.0 percent year-over-year. Shares of NuVasive have gained approximately 110.0 percent in the past year.
Get more information on NuVasive and free access to the in-depth equity report at:
www.FiveStarEquities.com/NUVA
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) shares declined 4.27 percent to close at $287.49 a share Wednesday. The stock traded between $286.02 and $295.88 on volume 1.34 million shares traded. Shares pulled back after spiking 12 percent Tuesday as the company announced better-than-expected sales figures for its drug Eylea. Shares of Regeneron Pharmaceuticals have gained approximately 60.0 percent in the past year.
Get more information on Regeneron Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/REGN
WellCare Health Plans, Inc. (NYSE: WCG) shares gained 2.35 percent to close at $72.71 a share Wednesday. The stock traded between $71.14 and $73.44 on volume 591,644 shares traded. In a recent regulatory filing the company stated that it expects premium revenue for 2013 to be in the range of $9.35 billion to $9.40 billion. Shares of WellCare Health Plans have gained approximately 55.0 percent in the past year.
Get more information on WellCare Health Plans and free access to the in-depth equity report at:
www.FiveStarEquities.com/WCG
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]